- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07399977
Met behulp van een bloedtest en softwaretool om de behandeling van veneuze trombo-embolie te begeleiden
Een niet-gerandomiseerde studie waarbij DNA-vloeistofbiopsies worden gebruikt om de antistolling te sturen voor patiënten met kanker-gerelateerde trombo-embolie
The purpose of this study is to find out whether a software tool, ctDNA/VTE (Venous Thromboembolism) risk score model, is an effective way to predict the likelihood of VTE coming back in people who have received anticoagulant treatment.
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Jeffrey Zwicker, MD
- Telefoonnummer: 646-608-3723
- E-mail: zwickerj@mskcc.org
Studie Contact Back-up
- Naam: Justin Jee, MD, PhD
- Telefoonnummer: 646-608-4409
- E-mail: jeej@mskcc.org
Studie Locaties
-
-
-
Sydney, Australië, 2065
- Nog niet aan het werven
- Royal North Shore Hospital, Australia
-
Contact:
- Adrian Lee, MBBS, FRACP PhD
- Telefoonnummer: 02 8037 4100
-
-
-
-
New Jersey
-
Basking Ridge, New Jersey, Verenigde Staten, 07920
- Werving
- Memorial Sloan Kettering Cancer Center Basking Ridge (All Protocol Activities)
-
Contact:
- Justin Jee, MD, PhD
- Telefoonnummer: 646-608-4409
-
Middletown, New Jersey, Verenigde Staten, 07748
- Werving
- Memorial Sloan Kettering Monmouth (All Protocol Activities)
-
Contact:
- Justin Jee, MD, PhD
- Telefoonnummer: 646-608-4409
-
Montvale, New Jersey, Verenigde Staten, 07645
- Werving
- Memorial Sloan Kettering Bergen (All Protocol Activities)
-
Contact:
- Justin Jee, MD, PhD
- Telefoonnummer: 646-608-4409
-
-
New York
-
Commack, New York, Verenigde Staten, 11725
- Werving
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)
-
Contact:
- Justin Jee, MD, PhD
- Telefoonnummer: 646-608-4409
-
Harrison, New York, Verenigde Staten, 10604
- Werving
- Memorial Sloan Kettering Westchester (All Protocol Activities)
-
Contact:
- Justin Jee, MD, PhD
- Telefoonnummer: 646-608-4409
-
New York, New York, Verenigde Staten, 10065
- Werving
- Memorial Sloan Kettering Cancer Center (All Protocol Activites)
-
Contact:
- Justin Jee, MD, PhD
- Telefoonnummer: 646-608-4409
-
Rockville Centre, New York, Verenigde Staten, 11553
- Werving
- Memorial Sloan Kettering Nassau (All protocol activities)
-
Contact:
- Justin Jee, MD, PhD
- Telefoonnummer: 646-608-4409
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age ≥ 18 with a history of cancer-associated VTE (objectively confirmed symptomatic or incidental/unsuspected proximal lower-limb DVT, symptomatic pulmonary embolism [PE] or incidental PE in a segmental or more proximal pulmonary artery) and completion of between 3 and 12 months of anticoagulation with enoxaparin, dalteparin,rivaroxaban, or apixaban without current VTE-related symptoms (imaging to confirm resolution not required).
Diagnosis of DVT requires evidence of one or more filling defects at compression ultrasonography, venography, CT venography, or MR venography involving at least the popliteal or more proximal veins.
Diagnosis of PE requires an intraluminal filling defect in segmental or more proximal arteries.
-
Diagnosis of one of the following solid tumors in either advanced (i.e. unresectable) stage or receiving systemic anticancer treatment within six weeks of enrollment (maintenance therapy included):
- breast cancer regardless of cytotoxic-chemotherapy status
- hepatobiliary cancer regardless of cytotoxic-chemotherapy status
- prostate cancer regardless of cytotoxic-chemotherapy status
- non-small cell lung cancer with cytotoxic-chemotherapy received within 30 days
- pancreatic cancer with cytotoxic-chemotherapy received within 30 days
- bladder cancer with cytotoxic-chemotherapy received within 30 days
-
Signed and dated informed consent by study participant/Legally Authorized Representative (LAR).
Exclusion Criteria:
- Contraindication to ongoing anticoagulation
- Contraindication to discontinuation of anticoagulation (examples include but not limited to: known antiphospholipid syndrome or factor V leiden, active arterial thrombus, catheter-associated thrombus, on anticoagulation for atrial fibrillation or other non-oncologic reasons)
- History of major bleeding in the last six months (major bleeding defined as fatal bleeding, and/or symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome; bleeding that necessitates acute surgical intervention; bleeding causing a fall in hemoglobin levels of 1.24 mmol/L (2 g/dL or greater) or more; or bleeding leading to a transfusion of 2 U or more of whole blood or red cells).
- Known diagnosis of disseminated intravascular coagulation (DIC)
- Suspicion for tumor thrombus on the imaging leading to original diagnosis of VTE
- Enrolled in hospice care
- Currently has inferior vena cava (IVC) filter
- Diagnosis of an active hematologic malignancy
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Diagnostisch
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: High risk for recurrent Venous Thromboembolism/VTE
Participants with a ≤5% chance of Venous Thromboembolism/VTE according to the model will be designated "low risk" for the purposes of the study; all other participants will be considered "high risk. |
MSK-ACCESS is a ctDNA sequencing assay Machine learning Venous Thromboembolism/VTE risk score mode |
|
Experimenteel: Low-risk for recurrent Venous Thromboembolism/VTE
Participants with a ≤5% chance of Venous Thromboembolism/VTE according to the model will be designated "low risk" for the purposes of the study; all other participants will be considered "high risk. |
MSK-ACCESS is a ctDNA sequencing assay Machine learning Venous Thromboembolism/VTE risk score mode |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Cumulative incidence of recurrent Venous Thromboembolism/VTE
Tijdsspanne: 6 months
|
Evaluate the cumulative incidence of recurrent Venous Thromboembolism/VTE at 6 months following discontinuation of anticoagulation in participants with low risk DNA liquid biopsy-based model. |
6 months
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Justine Jee, MD, PhD, Memorial Sloan Kettering Cancer Center
Publicaties en nuttige links
Nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 25-095
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .